HOME ·

LEADS BIOLABS-B

LEADS BIOLABS-B (09887.HK): Pivotal EP-NEC Study Selected as ESMO Late-Breaking Abstract
Tags：
NewTimeSpaceLEADS BIOLABS-B09887.HK
2026-09-21
LEADS BIOLABS-B (09887.HK): Updated Phase II Data of Vilxin® Combined with Chemotherapy as First-Line Treatment for NSCLC Presented in Oral Presentation at WCLC 2026
Tags：
LEADS BIOLABS-B09887.HKR&D Progress
2026-09-14
LEADS BIOLABS-B (09887.HK): NDA for Virexin as Treatment for Extrapulmonary Neuroendocrine Carcinoma Accepted by NMPA
Tags：
LEADS BIOLABS-B09887.HKR&D Progress
2026-08-21
LEADS BIOLABS-B (09887.HK): Phase II study abstract of Vimx (opasumivimab) as first-line NSCLC therapy published on WCLC website
Tags：
LEADS BIOLABS-B09887.HKClinical Progress
2026-08-20
LEADS BIOLABS-B (09887.HK): Oblenio exercises option to retain license for LBL-051, Company to receive USD 10 million
Tags：
LEADS BIOLABS-B09887.HKClinical Progress
2026-08-20
Nanjing Leads Biolabs-B (09887.HK): LBL-024 (WeilixinTM) Phase II Study for First-Line HCC Treatment Enters Expansion Stage
Tags：
LEADS BIOLABS-B09887.HK
2026-08-06
LEADS BIOLABS-B(09887.HK): Partner Oblenio Bio Completes First‑in‑Human Phase Ia First‑Patient Dosing of LBL‑051 for Refractory Autoimmune Diseases
Tags：
LEADS BIOLABS-B09887.HKClinical Trial
2026-08-04
LEADS BIOLABS-B (09887.HK): Six Research Abstracts Accepted for ESMO Congress 2026, Including Two Proffered Paper Presentations and LBA Eligibility
Tags：
LEADS BIOLABS-B09887.HKESMO
2026-07-13
LEADS BIOLABS-B (09887.HK): VELIXIN™ Granted Priority Review by NMPA for Advanced Extrapulmonary Neuroendocrine Carcinoma
Tags：
LEADS BIOLABS-B09887.HKNew Drug Application
2026-07-10
Leads Biolabs-B (09887.HK) Partner Oblenio Closes Oversubscribed $62M Series B Led by Pfizer Ventures
Tags：
LEADS BIOLABS-B09887.HK
2026-06-25
Leads Biolabs-B (09887.HK): Core Bispecific Antibody Initiates Phase Ib/II Trial for Triple-Negative Breast Cancer
Tags：
LEADS BIOLABS-B09887.HKClinical Trial
2026-02-10